Page 74 - GALENIKA MEDICAL JOURNAL

accepted blood tests for neuroinflammation, astrocytic, microglial activation in AD. However, both methods are either
invasive and/or very expensive at the same time, so great efforts have been made to determine basic and more specific
biomarkers in blood as a less invasive and more accessible procedure. In the primary health care setting, diagnostic
algorithms from blood could already be sufficient to improve the accuracy of the clinical diagnosis of AD dementia and
to positively influence the future treatment and care of people with cognitive problems. Additional studies are needed to
evaluate the optimal combination of plasma biomarkers with other accessible and cost-effective procedures, such as, for
example, MRI and cognitive tests, which are necessary for further development of predictive algorithms, which will be
especially important in non-demented patients with cognitive problems.

Keywords: Alzheimer's disease, biomarkers, clinical diagnosis

Literatura 16. Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA,
Jockel-Balsarotti J, et al. Tau Kinetics in Neurons and the Human Central
Nervous System. Neuron. 2018 May 16;98(4):861-4.
1. DeTure MA, Dickson DW. The neuropathological diagnosis of 17. Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K,
Alzheimer's disease. Mol Neurodegener. 2019 Aug 2;14(1):32. et al. Predicting clinical decline and conversion to Alzheimer's
2. Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF
Cerebrospinal fluid and plasma biomarker trajectories with increasing immunoassays. Sci Rep. 2019 Dec 13;9(1):19024.
amyloid deposition in Alzheimer's disease. EMBO Mol Med. 2019 18. De Vos A, Bjerke M, Brouns R, De Roeck N, Jacobs D, Van den Abbeele L,
Dec;11(12):e11170. et al. Neurogranin and tau in cerebrospinal fluid and plasma of patients
3. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. with acute ischemic stroke. BMC Neurol. 2017 Aug 30;17(1):170.
Neuron. 2013 Dec 18;80(6):1347-58. 19. Zetterberg H. Review: Tau in biofluids - relation to pathology, imaging
4. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade and clinical features. Neuropathol Appl Neurobiol. 2017 Apr;43(3):194-9.
hypothesis. Science. 1992 Apr 10;256(5054):184-5. 20. Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma
5. Cohen AD, Landau SM, Snitz BE, Klunk WE, Blennow K, Zetterberg H. phospho-tau181 increases with Alzheimer's disease clinical severity
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. and is associated with tau- and amyloid-positron emission tomography.
Mol Cell Neurosci. 2019 Jun;97:3-17. Alzheimers Dement. 2018 Aug;14(8):989-97.
6. Bogoslovsky T, Wilson D, Chen Y, Hanlon D, Gill J, Jeromin A, et al. 21. Pereira JB, Westman E, Hansson O; Alzheimer's Disease Neuroimaging
Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Initiative. Association between cerebrospinal fluid and plasma
Amyloid β up to 90 Days after Traumatic Brain Injury. J Neurotrauma. neurodegeneration biomarkers with brain atrophy in Alzheimer's
2017 Jan 1;34(1):66-73. disease. Neurobiol Aging. 2017 Oct;58:14-29.
7. Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, 22. Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al;
Rominger A, Alcolea D, Fortea J, et al. sTREM2 cerebrospinal fluid Advancing Research and Treatment for Frontotemporal Lobar
levels are a potential biomarker for microglia activity in early-stage Degeneration (ARTFL) investigators. Diagnostic value of plasma
Alzheimer's disease and associate with neuronal injury markers. EMBO phosphorylated tau181 in Alzheimer's disease and frontotemporal
Mol Med. 2016 May 2;8(5):466-76. lobar degeneration. Nat Med. 2020 Mar;26(3):387-397.
8. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 23. Braak H, Braak E. Neuropathological stageing of Alzheimer-related
years. EMBO Mol Med. 2016 Jun 1;8(6):595-608. changes. Acta Neuropathol. 1991;82(4):239-59.
9. Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, et 24. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE,
al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a et al. Plasma P-tau181 in Alzheimer's disease: relationship to other
systematic review and meta-analysis. Lancet Neurol. 2016 Jun;15(7):673- biomarkers, differential diagnosis, neuropathology and longitudinal
84. progression to Alzheimer's dementia. Nat Med. 2020 Mar;26(3):379-86.
10. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages 25. Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, et
and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019 Jun;97:18-33.
the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. 2019 Apr 26. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical
22;11(1):34. use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010
11. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Feb;6(2):67-77.
Herscovitch P, et al; Amyloid Imaging Task Force of the Alzheimer’s 27. Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS,
Association and Society for Nuclear Medicine and Molecular Imaging. et al. Alzheimer-signature MRI biomarker predicts AD dementia in
Update on appropriate use criteria for amyloid PET imaging: cognitively normal adults. Neurology. 2011 Apr 19;76(16):1395-402.
dementia experts, mild cognitive impairment, and education. Amyloid
Imaging Task Force of the Alzheimer’s Association and Society for 28. Vogt NM, Hunt JF, Adluru N, Dean DC, Johnson SC, Asthana S, et al.
Nuclear Medicine and Molecular Imaging. Alzheimers Dement. 2013 Cortical Microstructural Alterations in Mild Cognitive Impairment and
Jul;9(4):e106-9. Alzheimer's Disease Dementia. Cereb Cortex. 2020 May 14;30(5):2948-
12. Leitão MJ, Silva-Spínola A, Santana I, Olmedo V, Nadal A, Le Bastard N, 60.
et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays 29. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et
for routine diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2019 al. Neurofilaments as biomarkers in neurological disorders. Nat Rev
Nov 23;11(1):91. Neurol. 2018 Oct;14(10):577-89.
13. Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. 30. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg
Performance of Fully Automated Plasma Assays as Screening Tests for H. Neurofilament light chain as a biomarker in neurological disorders. J
Alzheimer Disease-Related β-Amyloid Status. JAMA Neurol. 2019 Sep Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-81.
1;76(9):1060-9.
31. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE;
14. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et and the NFL Group; Alvarez-Cermeño JC, Andreasson U, Axelsson
al. High-precision plasma β-amyloid 42/40 predicts current and future M, Bäckström DC, Bartos A, Bjerke M, et al. Diagnostic Value of
brain amyloidosis. Neurology. 2019 Oct 22;93(17):e1647-e1659. Cerebrospinal Fluid Neurofilament Light Protein in Neurology:
15. Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, et A Systematic Review and Meta-analysis. JAMA Neurol. 2019 Sep
1;76(9):1035-48.
al. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
Brain. 2015 Sep;138(Pt 9):2716-31.

72 DOI: 10.5937/Galmed2305068S